What is Applied Dna Scie's earnings per share (EPS)?

Applied Dna Scie (APDN) reported diluted earnings per share of $-134.23 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Applied Dna Scie Financials

APDN

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE September

This page shows Applied Dna Scie (APDN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI APDN FY2025 2026-04-22

Applied DNA Sciences looks like a development-stage business funded by repeated capital raises because operating burn far exceeds sales.

Between FY2024 and FY2025, revenue stayed near $2.1M, but R&D spending rose to $6.0M and operating cash burn stayed above $12.2M; with cash ending at only $1.7M and the current ratio slipping to 0.9x from 3.4x, the constraint is no longer demand alone but how long external funding can keep operations going.

The deeper FY2025 loss was not mainly a sales shock: revenue was roughly flat versus FY2024, SG&A edged down, yet gross profit fell to $839K while R&D expanded sharply, pointing to a deliberate increase in development spend rather than simple overhead drift.

Cash generation and accounting profit are telling the same story: net loss of $15.2M and operating cash outflow of $12.2M were close enough that the business is consuming real cash, not just recording non-cash charges. Financing inflow of $8.1M softened that drain but did not fully replace it, helping explain why the asset base fell to $4.4M from $12.8M in FY2024.

Financial Health Signals

Financial Health Score 31/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Applied Dna Scie's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Dilution

R&D Intensity

Revenue Progress

Burn Trend

Balance Sheet

Altman Z-Score Distress

-129.39

Applied Dna Scie scores -129.39, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($7.3M) relative to total liabilities ($2.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/8

Applied Dna Scie passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.81x

For every $1 of reported earnings, Applied Dna Scie generates $0.81 in operating cash flow (-$12.2M OCF vs -$15.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-83.2x

Applied Dna Scie earns $-83.2 in operating income for every $1 of interest expense (-$16.0M vs $193K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$2.1M

YoY+1.1%

5Y CAGR+2.0%

10Y CAGR-13.4%

Applied Dna Scie generated $2.1M in revenue in fiscal year 2025. This represents an increase of 1.1% from the prior year.

EBITDA

-$15.7M

YoY-18.3%

Applied Dna Scie's EBITDA was -$15.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 18.3% from the prior year.

Net Income

-$15.2M

YoY-116.8%

Applied Dna Scie reported -$15.2M in net income in fiscal year 2025. This represents a decrease of 116.8% from the prior year.

EPS (Diluted)

$-134.23

Applied Dna Scie earned $-134.23 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

-$12.6M

YoY+11.1%

Applied Dna Scie generated -$12.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 11.1% from the prior year.

Cash & Debt

$1.7M

YoY-71.5%

5Y CAGR-26.5%

10Y CAGR-13.7%

Applied Dna Scie held $1.7M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

Applied Dna Scie had 2M shares outstanding in fiscal year 2025.

Margins & Returns

Gross Margin

39.3%

YoY-6.9pp

5Y CAGR-23.4pp

10Y CAGR-56.5pp

Applied Dna Scie's gross margin was 39.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 6.9 percentage points from the prior year.

Operating Margin

-750.9%

YoY-104.2pp

5Y CAGR-101.9pp

10Y CAGR-663.7pp

Applied Dna Scie's operating margin was -750.9% in fiscal year 2025, reflecting core business profitability. This is down 104.2 percentage points from the prior year.

Net Margin

-709.5%

YoY-378.6pp

5Y CAGR-35.0pp

10Y CAGR-577.6pp

Applied Dna Scie's net profit margin was -709.5% in fiscal year 2025, showing the share of revenue converted to profit. This is down 378.6 percentage points from the prior year.

Return on Equity

-657.8%

YoY-581.3pp

5Y CAGR-430.0pp

10Y CAGR-563.3pp

Applied Dna Scie's ROE was -657.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 581.3 percentage points from the prior year.

Capital Allocation

R&D Spending

$6.0M

YoY+67.4%

5Y CAGR+12.6%

10Y CAGR+8.8%

Applied Dna Scie invested $6.0M in research and development in fiscal year 2025. This represents an increase of 67.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$313K

YoY-23.2%

5Y CAGR-21.7%

10Y CAGR-1.2%

Applied Dna Scie invested $313K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 23.2% from the prior year.

APDN Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$2.1M+1.1%	$2.1M-84.2%	$13.4M-26.4%	$18.2M+101.3%	$9.0M+367.4%	$1.9M
Cost of Revenue	$1.3M+14.0%	$1.1M-85.5%	$7.8M-40.3%	$13.1M+188.6%	$4.5M+530.4%	$721K
Gross Profit	$839K-13.9%	$975K-82.4%	$5.5M+9.5%	$5.1M+12.7%	$4.5M+270.3%	$1.2M
R&D Expenses	$6.0M+67.4%	$3.6M-3.8%	$3.7M-4.9%	$3.9M-5.7%	$4.2M+25.4%	$3.3M
SG&A Expenses	$10.9M-1.6%	$11.0M-13.3%	$12.8M-15.5%	$15.1M+17.5%	$12.8M+28.1%	$10.0M
Operating Income	-$16.0M-17.4%	-$13.7M-24.8%	-$11.0M+21.6%	-$14.0M-4.7%	-$13.3M-6.5%	-$12.5M
Interest Expense	$193K+9.4%	$176K+134.0%	$75K+946.3%	$7K-47.3%	$14K+111.8%	-$116K
Income Tax	-$684K	$0	$0	$0	$0	$0
Net Income	-$15.2M-116.8%	-$7.0M+29.7%	-$9.9M-20.3%	-$8.3M+42.1%	-$14.3M-9.7%	-$13.0M
EPS (Diluted)	$-134.23	$-1366.42-8883.7%	$-15.21	$-0.93+55.1%	$-2.07+37.7%	$-3.32

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$1.0M+81.1%	$565K+183.5%	$199K-34.5%	$304K-60.1%	$763K-12.3%	$870K	N/A	$473K
Cost of Revenue	$197K-21.1%	$250K-31.9%	$367K+22.8%	$299K-18.5%	$367K+39.1%	$264K	N/A	$230K
Gross Profit	$827K+162.2%	$315K+287.7%	-$168K-3374.5%	$5K-98.7%	$396K-34.8%	$606K	N/A	$243K
R&D Expenses	$372K-18.8%	$459K-86.4%	$3.4M+340.3%	$769K-9.5%	$849K-16.3%	$1.0M	N/A	$913K
SG&A Expenses	$2.6M-80.6%	$13.3M+446.0%	$2.4M-16.6%	$2.9M+0.2%	$2.9M+13.8%	$2.6M	N/A	$2.6M
Operating Income	-$6.8M+63.9%	-$18.7M-212.0%	-$6.0M-62.3%	-$3.7M-9.4%	-$3.4M-13.4%	-$3.0M	N/A	-$3.3M
Interest Expense	$4K-58.9%	$9K-56.2%	$21K-48.2%	$40K-33.3%	$60K-15.5%	$71K	N/A	$36K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$6.7M+64.2%	-$18.6M-252.7%	-$5.3M-33.6%	-$3.9M-19.4%	-$3.3M-25.2%	-$2.6M	N/A	$1.9M
EPS (Diluted)	$-0.68+67.3%	$-2.08	N/A	$-34.00	$-230.30	$-417.53	N/A	$1170.48

APDN Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$4.4M-65.3%	$12.8M-6.3%	$13.7M-38.7%	$22.3M+54.4%	$14.4M+27.1%	$11.3M
Current Assets	$2.2M-72.2%	$8.0M-1.0%	$8.1M-59.3%	$19.9M+76.5%	$11.3M+24.5%	$9.1M
Cash & Equivalents	$1.7M-71.5%	$5.9M-18.2%	$7.2M-53.0%	$15.2M+132.1%	$6.6M-15.8%	$7.8M
Inventory	$84K-80.6%	$433K+31.1%	$330K-45.2%	$602K-56.0%	$1.4M+175.4%	$497K
Accounts Receivable	$237K-27.7%	$328K+28.5%	$256K-91.7%	$3.1M+9.4%	$2.8M+1343.0%	$194K
Goodwill	N/A	N/A	N/A	N/A	N/A	$285K
Total Liabilities	$2.5M-34.7%	$3.8M-56.5%	$8.8M-6.2%	$9.4M+183.2%	$3.3M-41.3%	$5.6M
Current Liabilities	$2.5M+2.7%	$2.4M-15.7%	$2.8M-32.0%	$4.2M+27.9%	$3.3M-23.3%	$4.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$2.3M-74.8%	$9.1M+84.7%	$5.0M-61.7%	$12.9M+16.2%	$11.1M+94.4%	$5.7M
Retained Earnings	-$379.2M-22.4%	-$309.7M-2.4%	-$302.4M-3.4%	-$292.5M-2.9%	-$284.1M-5.3%	-$269.8M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$13.6M-34.1%	$20.7M+366.4%	$4.4M-55.3%	$9.9M-23.8%	$13.0M-18.4%	$16.0M+24.9%	$12.8M-23.4%	$16.7M
Current Assets	$2.7M-47.6%	$5.1M+128.4%	$2.2M-60.2%	$5.6M-33.2%	$8.4M-25.2%	$11.3M+40.1%	$8.0M-32.0%	$11.8M
Cash & Equivalents	$949K-61.3%	$2.5M+46.9%	$1.7M-64.7%	$4.7M-30.7%	$6.8M-26.6%	$9.3M+58.8%	$5.9M-44.0%	$10.4M
Inventory	$115K+28.3%	$90K+7.0%	$84K-75.2%	$339K-2.9%	$349K-25.5%	$469K+8.3%	$433K-7.9%	$470K
Accounts Receivable	$303K-44.5%	$547K+130.3%	$237K+19.3%	$199K-71.1%	$690K-24.3%	$912K+177.7%	$328K-36.1%	$514K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.5M-32.7%	$2.2M-10.4%	$2.5M-15.3%	$2.9M+4.8%	$2.8M-17.8%	$3.4M-10.5%	$3.8M-14.2%	$4.5M
Current Liabilities	$1.5M-33.2%	$2.2M-10.5%	$2.5M+21.0%	$2.0M+7.5%	$1.9M-20.6%	$2.4M-0.5%	$2.4M-20.7%	$3.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$12.5M-33.6%	$18.8M+717.3%	$2.3M-68.3%	$7.3M-30.6%	$10.5M-18.0%	$12.8M+39.5%	$9.1M-26.2%	$12.4M
Retained Earnings	-$404.5M-1.7%	-$397.8M-4.9%	-$379.2M-1.4%	-$373.9M-5.5%	-$354.4M-8.3%	-$327.2M-5.7%	-$309.7M-1.1%	-$306.4M

APDN Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$12.2M+10.7%	-$13.7M-120.5%	-$6.2M+30.7%	-$9.0M+32.9%	-$13.4M-20.1%	-$11.1M
Capital Expenditures	$313K-23.2%	$408K+420.0%	$78K-84.0%	$490K-80.8%	$2.5M+139.6%	$1.1M
Free Cash Flow	-$12.6M+11.1%	-$14.1M-124.3%	-$6.3M+33.5%	-$9.5M+40.6%	-$15.9M-30.6%	-$12.2M
Investing Cash Flow	N/A	-$408K+62.8%	-$1.1M-123.8%	-$490K+80.8%	-$2.5M-139.6%	-$1.1M
Financing Cash Flow	$8.1M-39.9%	$13.4M	N/A	$18.1M+23.3%	$14.7M-24.3%	$19.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$2.0M+63.0%	-$5.5M-78.8%	-$3.1M-19.1%	-$2.6M+19.0%	-$3.2M+3.4%	-$3.3M+1.8%	-$3.4M-1.0%	-$3.4M
Capital Expenditures	N/A	N/A	$0-100.0%	$11K-94.1%	$185K+58.6%	$117K-68.5%	$371K+1601.0%	$22K
Free Cash Flow	N/A	N/A	-$3.1M-18.7%	-$2.6M+23.1%	-$3.4M+1.3%	-$3.4M+8.4%	-$3.8M-11.3%	-$3.4M
Investing Cash Flow	$0+100.0%	-$3.0M	N/A	N/A	-$185K-58.6%	-$117K+68.5%	-$371K-1601.0%	-$22K
Financing Cash Flow	-$203K-102.2%	$9.3M+7295.3%	$126K-82.6%	$723K-19.6%	$899K-85.7%	$6.3M+1714.1%	-$391K-103.6%	$10.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

APDN Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	39.3%-6.9pp	46.1%+4.7pp	41.4%+13.6pp	27.8%-21.8pp	49.7%-13.0pp	62.7%
Operating Margin	-750.9%-104.2pp	-646.7%-564.8pp	-81.9%-5.0pp	-76.9%+71.0pp	-147.9%+501.1pp	-649.0%
Net Margin	-709.5%-378.6pp	-330.9%-256.4pp	-74.4%-28.9pp	-45.5%+112.7pp	-158.3%+516.2pp	-674.5%
Return on Equity	-657.8%-581.3pp	-76.5%+124.4pp	-200.9%-136.9pp	-64.0%+64.5pp	-128.6%+99.3pp	-227.8%
Return on Assets	-341.7%-287.0pp	-54.7%+18.2pp	-72.9%-35.7pp	-37.1%+62.0pp	-99.1%+15.8pp	-114.9%
Current Ratio	0.91-2.4	3.36+0.5	2.86-1.9	4.76+1.3	3.45+1.3	2.13
Debt-to-Equity	1.08+0.7	0.42-1.4	1.77+1.0	0.72+0.4	0.30-0.7	0.98
FCF Margin	-587.6%+80.5pp	-668.1%-621.0pp	-47.1%+5.0pp	-52.1%+124.4pp	-176.5%+455.4pp	-632.0%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	80.7%+25.0pp	55.8%+140.0pp	-84.2%-85.9pp	1.7%-50.2pp	51.8%-17.8pp	69.7%	N/A	51.3%
Operating Margin	-659.2%+2649.7pp	-3308.9%-301.8pp	-3007.1%-1793.5pp	-1213.6%-770.8pp	-442.8%-100.6pp	-342.2%	N/A	-699.3%
Net Margin	-650.8%+2637.8pp	-3288.6%-645.2pp	-2643.4%-1347.3pp	-1296.1%-863.0pp	-433.2%-129.9pp	-303.3%	N/A	397.6%
Return on Equity	-53.3%+45.4pp	-98.7%+130.0pp	-228.7%-174.4pp	-54.3%-22.7pp	-31.6%-10.9pp	-20.7%	N/A	15.2%
Return on Assets	-48.9%+41.0pp	-89.8%+29.0pp	-118.8%-79.1pp	-39.7%-14.4pp	-25.4%-8.8pp	-16.5%	N/A	11.3%
Current Ratio	1.82-0.5	2.32+1.4	0.91-1.9	2.76-1.7	4.45-0.3	4.72+1.4	3.36-0.6	3.91
Debt-to-Equity	0.120.0	0.12-1.0	1.08+0.7	0.41+0.1	0.270.0	0.27-0.1	0.42+0.1	0.36
FCF Margin	N/A	N/A	-1554.9%-696.3pp	-858.6%-413.1pp	-445.5%-49.9pp	-395.6%	N/A	-714.4%

Note: The current ratio is below 1.0 (0.91), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Endra Life Sciences Inc NDRA

$7.1M

Check Cap CHEK

$9.4M

XWELL Inc XWEL

$9.1M

Mainz Biomed NV MYNZ

$10.6M

bioAffinity Tech BIAF

$4.5M

Frequently Asked Questions

What is Applied Dna Scie's annual revenue?

Applied Dna Scie (APDN) reported $2.1M in total revenue for fiscal year 2025. This represents a 1.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Applied Dna Scie's revenue growing?

Applied Dna Scie (APDN) revenue grew by 1.1% year-over-year, from $2.1M to $2.1M in fiscal year 2025.

Is Applied Dna Scie profitable?

No, Applied Dna Scie (APDN) reported a net income of -$15.2M in fiscal year 2025, with a net profit margin of -709.5%.

What is Applied Dna Scie's EBITDA?

Applied Dna Scie (APDN) had EBITDA of -$15.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Applied Dna Scie's gross margin?

Applied Dna Scie (APDN) had a gross margin of 39.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Applied Dna Scie's operating margin?

Applied Dna Scie (APDN) had an operating margin of -750.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Applied Dna Scie's net profit margin?

Applied Dna Scie (APDN) had a net profit margin of -709.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Applied Dna Scie's return on equity (ROE)?

Applied Dna Scie (APDN) has a return on equity of -657.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Applied Dna Scie's free cash flow?

Applied Dna Scie (APDN) generated -$12.6M in free cash flow during fiscal year 2025. This represents a 11.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Applied Dna Scie's operating cash flow?

Applied Dna Scie (APDN) generated -$12.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Applied Dna Scie's total assets?

Applied Dna Scie (APDN) had $4.4M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Applied Dna Scie's capital expenditures?

Applied Dna Scie (APDN) invested $313K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Applied Dna Scie spend on research and development?

Applied Dna Scie (APDN) invested $6.0M in research and development during fiscal year 2025.

How many shares does Applied Dna Scie have outstanding?

Applied Dna Scie (APDN) had 2M shares outstanding as of fiscal year 2025.

What is Applied Dna Scie's current ratio?

Applied Dna Scie (APDN) had a current ratio of 0.91 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Applied Dna Scie's debt-to-equity ratio?

Applied Dna Scie (APDN) had a debt-to-equity ratio of 1.08 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Applied Dna Scie's return on assets (ROA)?

Applied Dna Scie (APDN) had a return on assets of -341.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Applied Dna Scie's cash runway?

Based on fiscal year 2025 data, Applied Dna Scie (APDN) had $1.7M in cash against an annual operating cash burn of $12.2M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Applied Dna Scie's Altman Z-Score?

Applied Dna Scie (APDN) has an Altman Z-Score of -129.39, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Applied Dna Scie's Piotroski F-Score?

Applied Dna Scie (APDN) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Applied Dna Scie's earnings high quality?

Applied Dna Scie (APDN) has an earnings quality ratio of 0.81x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Applied Dna Scie cover its interest payments?

Applied Dna Scie (APDN) has an interest coverage ratio of -83.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Applied Dna Scie?

Applied Dna Scie (APDN) scores 31 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.